Division of Pediatric Hematology Oncology, The University of Alabama at Birmingham, Birmingham, AL.
Department of Biostatistics, The University of Alabama at Birmingham, Birmingham, AL.
Blood Adv. 2023 Nov 28;7(22):6850-6858. doi: 10.1182/bloodadvances.2023010101.
It is critical to characterize the natural history of albuminuria in patients with sickle cell anemia (SCA); however, these data are currently lacking and affecting evidence-based guidelines. We performed a natural history study of the development of pediatric albuminuria. We identified participants with hemoglobin SS/SB0 thalassemia ≥5 years with albumin to creatinine ratio (ACR) measurements performed at a steady-state clinic visit. Participants were characterized as either persistent, intermittent, or never albuminuria. We determined the prevalence of persistent albuminuria, use of ACR ≥100 mg/g as a predictor, and variation in ACR measurements. We mirrored this study to determine the variation in albuminuria measurements in the SCA murine model. Among 355 participants with HbSS/SB0 thalassemia with 1728 ACR measurements, we identified 17% with persistent and 13% with intermittent albuminuria. Thirteen percent of participants with persistent albuminuria developed an abnormal ACR before 10 years of age. A single ACR measurement ≥100 mg/g was associated with 55.5 times (95% confidence interval, 12.3-527) higher odds of having persistent albuminuria. Among participants with ACR ≥100 mg/g, we identified significant variability in the results of repeated measurements. The median ACR at the initial and next measurements were 175.8 mg/g (interquartile range [IQR], 135-242) and 117.3 mg/g (IQR, 64-292). The human variability in ACR was mirrored by ∼20% variability in albuminuria in murine model. This evidence suggests adopting standards for repeating ACR measurements, consider screening for ACR before 10 years of age, and using an ACR >100 mg/g as a risk factor for progression. Pediatric and murine renoprotective clinical trials need to consider the high variability in repeated ACR measurements.
阐明镰状细胞贫血(SCA)患者白蛋白尿的自然病程至关重要;然而,目前缺乏这些数据,影响了循证指南的制定。我们对儿科白蛋白尿的发展进行了自然病史研究。我们鉴定了血红蛋白 SS/SB0 地中海贫血≥5 岁且在稳定期临床就诊时进行白蛋白与肌酐比值(ACR)检测的参与者。参与者的特征为持续性、间歇性或无白蛋白尿。我们确定了持续性白蛋白尿的患病率、使用 ACR≥100mg/g 作为预测指标以及 ACR 检测值的变化。我们复制了这项研究,以确定 SCA 鼠模型中白蛋白尿检测值的变化。在 355 名血红蛋白 SS/SB0 地中海贫血患者中有 1728 次 ACR 检测值,我们发现 17%的患者存在持续性白蛋白尿,13%的患者存在间歇性白蛋白尿。13%的持续性白蛋白尿患者在 10 岁之前出现 ACR 异常。单次 ACR 检测值≥100mg/g 与持续性白蛋白尿的发生几率增加 55.5 倍(95%置信区间,12.3-527)相关。在 ACR≥100mg/g 的参与者中,我们发现重复测量结果存在显著差异。初始和下一次测量的 ACR 中位数分别为 175.8mg/g(四分位距[IQR],135-242)和 117.3mg/g(IQR,64-292)。鼠模型中白蛋白尿的变化约为 20%,这与人类 ACR 的变异性相似。这一证据表明,应采用重复 ACR 检测值的标准,考虑在 10 岁之前筛查 ACR,并将 ACR>100mg/g 作为进展的风险因素。儿科和鼠类肾脏保护临床试验需要考虑到重复 ACR 检测值的高度变异性。